ICU Medical (ICUI) Stock Price, News & Analysis

Company Overview

ICU Medical, Inc. (NASDAQ: ICUI), headquartered in San Clemente, California, is a global manufacturer of infusion therapy and critical care medical devices. The company designs, develops and provides a broad range of products focused on vascular access, infusion management and safety for acute and ambulatory care settings. Its solutions include needle-free connectors, IV sets, catheters and infusion pumps, which aim to improve clinical efficiency, patient comfort and healthcare worker protection.

Established in 1984 by George S. Demetri, ICU Medical initially gained prominence through pioneering needle-free IV systems that reduced needlestick injuries and contamination risks. Over the years, the company has expanded its portfolio and geographical reach, notably completing the acquisition of Hospira’s global infusion systems business in 2017. This strategic move strengthened ICU Medical’s position in Europe, Latin America, Asia-Pacific and North America, adding established drug-delivery platforms and manufacturing facilities to its operations.

ICU Medical operates two primary business segments: Infusion Therapy and Critical Care. The Infusion Therapy segment offers devices such as IV catheters, protective device systems and electronic infusion pumps, while the Critical Care segment provides products for oncology drug compound safety, hemodynamic monitoring and closed system transfer devices (CSTDs). This diversified offering enables ICU Medical to address a variety of clinical challenges, from infection control to precision drug delivery, across hospitals, clinics and ambulatory care centers.

Supported by an experienced executive leadership team and a board of directors, ICU Medical continues to invest in research and development to introduce innovative solutions that enhance patient safety and clinical outcomes. The company’s global manufacturing footprint and direct sales channels enable it to serve healthcare providers in over 100 countries, reinforcing its commitment to high-quality standards, regulatory compliance and continuous customer engagement.

Key Stats

• Today's Range: $129.76 to $133.63
• 50-Day Range: $127.74 to $144.34
• 52-Week Range: $117.92 to $196.26
• Volume: 184,139 shs
• Average Volume: 258,763 shs
• Market Capitalization: $3.26 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $192.67
• Consensus Rating: Buy

ICU Medical Stock Analysis - MarketRank™

ICU Medical scored higher than 92% of companies evaluated by MarketBeat, and ranked 98th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ICU Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

ICU Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 32.36%

Earnings Growth

Earnings for ICU Medical are expected to grow by 32.36% in the coming year, from $4.11 to $5.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ICU Medical is -34.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ICU Medical is -34.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ICU Medical has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.85% of the float of ICU Medical has been sold short.

Short Interest Ratio / Days to Cover

ICU Medical has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in ICU Medical has recently increased by 3.77%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ICU Medical does not currently pay a dividend.

Dividend Growth

ICU Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.47

Percentage of Shares Shorted

4.85% of the float of ICU Medical has been sold short.

Short Interest Ratio / Days to Cover

ICU Medical has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in ICU Medical has recently increased by 3.77%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.03

News Sentiment

ICU Medical has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ICU Medical this week, compared to 6 articles on an average week.

Search Interest

2 people have searched for ICUI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ICU Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,860,156.00 in company stock.

Percentage Held by Insiders

Only 1.50% of the stock of ICU Medical is held by insiders.

Percentage Held by Institutions

96.10% of the stock of ICU Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ICUI Stock Analysis - Frequently Asked Questions

How have ICUI shares performed this year?

ICU Medical's stock was trading at $155.17 on January 1st, 2025. Since then, ICUI stock has decreased by 14.6% and is now trading at $132.54.

How were ICU Medical's earnings last quarter?

ICU Medical, Inc. (NASDAQ:ICUI) announced its quarterly earnings data on Thursday, May, 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical's revenue was up 6.7% compared to the same quarter last year.
Read the conference call transcript.

Who are ICU Medical's major shareholders?

Top institutional shareholders of ICU Medical include Pacific Capital Partners Ltd (0.21%). Insiders that own company stock include George A Lopez, Vivek Jain, Daniel Woolson, David C Greenberg, Christian B Voigtlander, Virginia Ruth Sanzone, Elisha W Finney and Ben Sousa.
View institutional ownership trends.

How do I buy shares of ICU Medical?

Shares of ICUI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ICU Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ICU Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:ICUI
• CIK: 883984
• Web: www.icumed.com
• Phone: (949) 366-2183
• Fax: 949-366-8368
• Employees: 15,000
• Year Founded: 1984

Price Target and Rating

• Average Price Target for ICU Medical: $192.67
• High Price Target: $200.00
• Low Price Target: $187.00
• Potential Upside/Downside: +45.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 32.25
• P/E Growth: N/A
• Net Income: -$117.69 million
• Net Margins: -3.87%
• Pretax Margin: -1.66%
• Return on Equity: 6.75%
• Return on Assets: 3.20%

Debt

• Debt-to-Equity Ratio: 0.75
• Current Ratio: 2.59
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: $2.38 billion
• Price / Sales: 1.37
• Cash Flow: $14.33 per share
• Price / Cash Flow: 9.25
• Book Value: $80.26 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 24,610,000
• Free Float: 24,243,000
• Market Cap: $3.26 billion
• Optionable: Optionable
• Beta: 0.87